GlassScriptPhysician profile
Lisa D Hobson-Webb
NPI 1871715391
$11,831.12
in general payments reported to CMS, 2019-2025
5 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2022: $164 · 2023: $1,770 · 2024: $9,523 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,965 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,640 · Food and Beverage: $468 · Travel and Lodging: $299 · Education: $44.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,965.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,640.00 |
| Food and Beverage | $467.94 |
| Travel and Lodging | $299.25 |
| Education | $44.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $8,543.35 | 2023-2024 | Ultomiris |
| Csl Behring | $2,640.00 | 2024 | Privigen, Hizentra |
| Cadwell Industries, INC | $362.15 | 2019-2024 | |
| Argenx US, INC. | $267.74 | 2022-2025 | Vyvgart |
| Canon Medical Systems USA, INC. | $17.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Hobson-Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.